171 related articles for article (PubMed ID: 22688001)
1. Osteosarcoma in Sprague-Dawley rats after long-term treatment with teriparatide (human parathyroid hormone (1-34)).
Watanabe A; Yoneyama S; Nakajima M; Sato N; Takao-Kawabata R; Isogai Y; Sakurai-Tanikawa A; Higuchi K; Shimoi A; Yamatoya H; Yoshida K; Kohira T
J Toxicol Sci; 2012; 37(3):617-29. PubMed ID: 22688001
[TBL] [Abstract][Full Text] [Related]
2. Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose.
Vahle JL; Long GG; Sandusky G; Westmore M; Ma YL; Sato M
Toxicol Pathol; 2004; 32(4):426-38. PubMed ID: 15204966
[TBL] [Abstract][Full Text] [Related]
3. Safety of parathyroid hormone for the treatment of osteoporosis.
Miller PD
Curr Osteoporos Rep; 2008 Mar; 6(1):12-6. PubMed ID: 18430395
[TBL] [Abstract][Full Text] [Related]
4. The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis.
Orwoll ES; Scheele WH; Paul S; Adami S; Syversen U; Diez-Perez A; Kaufman JM; Clancy AD; Gaich GA
J Bone Miner Res; 2003 Jan; 18(1):9-17. PubMed ID: 12510800
[TBL] [Abstract][Full Text] [Related]
5. Of mice and men: divergent risks of teriparatide-induced osteosarcoma.
Subbiah V; Madsen VS; Raymond AK; Benjamin RS; Ludwig JA
Osteoporos Int; 2010 Jun; 21(6):1041-5. PubMed ID: 19597911
[TBL] [Abstract][Full Text] [Related]
6. Recombinant human parathyroid hormone. Preclinical data on rat osteosarcoma were not dismissed.
Kuijpers G; Schneider B; Stadel B; Colman E
BMJ; 2002 May; 324(7347):1218; author reply 1218. PubMed ID: 12016199
[No Abstract] [Full Text] [Related]
7. Defining a noncarcinogenic dose of recombinant human parathyroid hormone 1-84 in a 2-year study in Fischer 344 rats.
Jolette J; Wilker CE; Smith SY; Doyle N; Hardisty JF; Metcalfe AJ; Marriott TB; Fox J; Wells DS
Toxicol Pathol; 2006; 34(7):929-40. PubMed ID: 17178693
[TBL] [Abstract][Full Text] [Related]
8. Toxicology and carcinogenesis studies of pulegone (CAS No. 89-82-7) in F344/N rats and B6C3F1 mice (gavage studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2011 Aug; (563):1-201. PubMed ID: 21921962
[TBL] [Abstract][Full Text] [Related]
9. Challenges in studying very rare cancer outcomes and infrequent exposures: example of teriparatide and osteosarcoma.
Andrews EB; Gilsenan A; Midkiff K; Harris D
Ann Epidemiol; 2016 Nov; 26(11):751-753. PubMed ID: 27645108
[No Abstract] [Full Text] [Related]
10. Probable osteosarcoma risk after prolonged teriparatide treatment: comment on the article by Saag et al.
Tastekin N; Zateri C
Arthritis Rheum; 2010 Jun; 62(6):1837; author reply 1837-8. PubMed ID: 20191586
[No Abstract] [Full Text] [Related]
11. The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years.
Andrews EB; Gilsenan AW; Midkiff K; Sherrill B; Wu Y; Mann BH; Masica D
J Bone Miner Res; 2012 Dec; 27(12):2429-37. PubMed ID: 22991313
[TBL] [Abstract][Full Text] [Related]
12. Toxicology and carcinogenesis studies of p-nitrotoluene (CAS no. 99-99-0) in F344/N rats and B6C3F(1) mice (feed studies).
National Toxicology Program
Natl Toxicol Program Tech Rep Ser; 2002 May; (498):1-277. PubMed ID: 12118261
[TBL] [Abstract][Full Text] [Related]
13. Comparing the incidence of bone tumors in rats chronically exposed to the selective PTH type 1 receptor agonist abaloparatide or PTH(1-34).
Jolette J; Attalla B; Varela A; Long GG; Mellal N; Trimm S; Smith SY; Ominsky MS; Hattersley G
Regul Toxicol Pharmacol; 2017 Jun; 86():356-365. PubMed ID: 28389324
[TBL] [Abstract][Full Text] [Related]
14. Osteosarcoma and teriparatide?
Harper KD; Krege JH; Marcus R; Mitlak BH
J Bone Miner Res; 2007 Feb; 22(2):334. PubMed ID: 17129179
[No Abstract] [Full Text] [Related]
15. NTP technical report on the toxicology and carcinogenesis studies of Elmiron (Cas No. 37319-17-8) in F344/N rats and B6C3F1 mice (Gavage Studies).
National Toxicology Program, Public Health Services, National Institutes of Health, US Department of Health and Human Services,
Natl Toxicol Program Tech Rep Ser; 2004 May; (512):7-289. PubMed ID: 15213766
[TBL] [Abstract][Full Text] [Related]
16. Toxicology and carcinogenesis studies of o-nitrotoluene sulfone (CAS no. 88-72-2) in F344/N rats and B6C3F(1) mice (feed studies).
National Toxicology Program, Public Health Service, National Institutes of Health, US Department of Health and Human Services
Natl Toxicol Program Tech Rep Ser; 2002 May; (504):1-357. PubMed ID: 12087420
[TBL] [Abstract][Full Text] [Related]
17. Assessing the incidence of osteosarcoma among teriparatide-treated patients using linkage of commercial pharmacy and state cancer registry data, contributing to the removal of boxed warning and other labeling changes.
Kellier-Steele N; Casso D; Anderson A; Oliveria SA; Motsko S
Bone; 2022 Jul; 160():116394. PubMed ID: 35318162
[TBL] [Abstract][Full Text] [Related]
18. Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety.
Vahle JL; Sato M; Long GG; Young JK; Francis PC; Engelhardt JA; Westmore MS; Linda Y; Nold JB
Toxicol Pathol; 2002; 30(3):312-21. PubMed ID: 12051548
[TBL] [Abstract][Full Text] [Related]
19. The bone growth-stimulating PTH and osteosarcoma.
Whitfield JF
Medscape Womens Health; 2001 Oct; 6(5):7. PubMed ID: 11698929
[No Abstract] [Full Text] [Related]
20. Assessing the incidence of osteosarcoma among teriparatide users based on Medicare Part D and US State Cancer Registry Data.
Gilsenan A; Midkiff K; Harris D; McQuay L; Hunter S; Kellier-Steele N; Andrews E
Pharmacoepidemiol Drug Saf; 2020 Dec; 29(12):1616-1626. PubMed ID: 32894794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]